We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights AbbVie, The Boeing Company, Infosys Limited, Ford Motor Company and Public Storage
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 10, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. (ABBV - Free Report) , The Boeing Company (BA - Free Report) , Infosys Limited (INFY - Free Report) , Ford Motor Company (F - Free Report) and Public Storage (PSA - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for AbbVie, Boeing and Infosys
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., The Boeing Company, and Infosys Limited. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Shares of AbbVie have outperformed the Large-Cap Pharmaceuticals over the past year (+44.4% vs. +20.6%). The Zacks analyst believes that AbbVie has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023.
AbbVie has also been successfully expanding the labels of its cancer drugs, Imbruvica and Venclexta. Allergan’s acquisition has diversified AbbVie’s revenue base and enhanced its long-term growth potential. Sales erosion due to direct biosimilar competition to Humira in international markets remains a major concern, though.
Boeing shares have gained +6% in the year to date period against the Zacks Aerospace & Defense industry’s rise of +3.2%. The Zacks analyst believes that long-term prospects of the global services unit and increasing fiscal defense budget are expected to boost Boeing's growth.
Keeping up with the trend witnessed in the past couple of quarters, in the fourth quarter, Boeing witnessed solid recovery in its commercial business, particularly in domestic air traffic, which rebounded to around 90% of pre-pandemic levels in countries such as the United States and Brazil. Risks related to supply chain shortages due to COVID-19 pandemic and lower deliveries compared to Airbus raise concerns, though.
Shares of Infosys have gained +1.3% in the last six months against the Zacks Computers - IT Services industry’s loss of -10.5%. The Zacks analyst believes that Infosys has been benefiting from large deal wins and fast-growing digital services.
Focus on Agile Digital and artificial intelligence-driven Core services is a tailwind. Strong demand for its services in cloud, Internet of Things, cyber security, data and analytics remains a key driver. Infosys is, however, suffering from increasing anti-outsourcing sentiments in certain parts of the world. Higher subcontractor costs and INFY’s revised compensation that includes higher variable pay and incentives have also been weighing on margins.
Other noteworthy reports we are featuring today include Ford Motor Company and Public Storage .
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
The Zacks Analyst Blog Highlights AbbVie, The Boeing Company, Infosys Limited, Ford Motor Company and Public Storage
For Immediate Release
Chicago, IL – February 10, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. (ABBV - Free Report) , The Boeing Company (BA - Free Report) , Infosys Limited (INFY - Free Report) , Ford Motor Company (F - Free Report) and Public Storage (PSA - Free Report) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for AbbVie, Boeing and Infosys
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc., The Boeing Company, and Infosys Limited. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Shares of AbbVie have outperformed the Large-Cap Pharmaceuticals over the past year (+44.4% vs. +20.6%). The Zacks analyst believes that AbbVie has several new drugs in its portfolio, which have the potential to drive revenues once Humira loses U.S. exclusivity in 2023.
AbbVie has also been successfully expanding the labels of its cancer drugs, Imbruvica and Venclexta. Allergan’s acquisition has diversified AbbVie’s revenue base and enhanced its long-term growth potential. Sales erosion due to direct biosimilar competition to Humira in international markets remains a major concern, though.
(You can read the full research report on AbbVie here >>>)
Boeing shares have gained +6% in the year to date period against the Zacks Aerospace & Defense industry’s rise of +3.2%. The Zacks analyst believes that long-term prospects of the global services unit and increasing fiscal defense budget are expected to boost Boeing's growth.
Keeping up with the trend witnessed in the past couple of quarters, in the fourth quarter, Boeing witnessed solid recovery in its commercial business, particularly in domestic air traffic, which rebounded to around 90% of pre-pandemic levels in countries such as the United States and Brazil. Risks related to supply chain shortages due to COVID-19 pandemic and lower deliveries compared to Airbus raise concerns, though.
(You can read the full research report on Boeing here >>>)
Shares of Infosys have gained +1.3% in the last six months against the Zacks Computers - IT Services industry’s loss of -10.5%. The Zacks analyst believes that Infosys has been benefiting from large deal wins and fast-growing digital services.
Focus on Agile Digital and artificial intelligence-driven Core services is a tailwind. Strong demand for its services in cloud, Internet of Things, cyber security, data and analytics remains a key driver. Infosys is, however, suffering from increasing anti-outsourcing sentiments in certain parts of the world. Higher subcontractor costs and INFY’s revised compensation that includes higher variable pay and incentives have also been weighing on margins.
(You can read the full research report on Infosys here >>>)
Other noteworthy reports we are featuring today include Ford Motor Company and Public Storage .
5 Stocks Set to Double
Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in 2021. Previous recommendations have soared +143.0%, +175.9%, +498.3% and +673.0%.
Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.
Today, See These 5 Potential Home Runs >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.